Outcomes associated with CD3xCD20 bispecific antibody therapies in relapsed/refractory transformed indolent lymphoma
Year: 2026
Type: article
Study design: Observational Study
Abstract: Transformed indolent non-Hodgkin lymphoma (tiNHL) has historically been associated with poor outcomes, particularly for patients with relapsed or refractory (R/R) disease. Although chimeric antigen receptor (CAR) T-cell therapy has improved prognosis, many patients lack access or experience relapse following treatment, highlighting the need for additional therapeutic strategies. CD3×CD20 bispecific antibodies (BsAbs) are active in R/R large B-cell lymphoma (LBCL), though data in tiNHL are limited. Here, we report the efficacy and safety of epcoritamab and glofitamab in patients with R/R tiNHL (N = 74) compared with those of patients with R/R de novo diffuse LBCL (DLBCL; N = 166) from 9 academic centers in the Collaborative US Bispecifics Consortium (CUBIC). With a median follow-up of 11.5 months, best overall response rate (ORR) and complete response rate (CRR) were comparable in tiNHL (50%/31%) vs de novo DLBCL (51%/34%). 12-month progression-free survival was 25% (95% confidence interval [CI], 15-39) for tiNHL vs 34% (95% CI, 27-43) for de novo DLBCL (HR, 1.15 [95% CI, 0.83-1.61]) and 12-month overall survival was 38% (95% CI, 26-55) for tiNHL vs 47% (95% CI, 39-56) for de novo DLBCL (HR, 1.08 [95% CI, 0.73-1.60]). No differences in toxicity were observed. Similar findings were found via a 1:1 propensity score matching statistical approach. In conclusion, our study revealed comparable efficacy and toxicity of BsAbs for patients with R/R tiNHL vs patients with R/R de novo DLBCL, supporting their use in this patient population.
Source: Haematologica
Authors: Pierre Stephan, Karan L. Chohan, Robert A. Redd, Wendy Dixon, Aaron Zou, Sairah Ahmed, Christopher R. Flowers, Ayushi Chauhan, Amy A. Ayers, Geoffrey Shouse, Swetha Kambhampati Thiruvengadam, Alex F. Herrera, Allison M. Bock, Narendranath Epperla, Matthew A. Lunning, Gilles Salles, Lorenzo Falchi, Yazeed Sawalha, Sonia Godbole, Andrew P. Jallouk, Shakthi T. Bhaskar, Ajay Major, Steven M. Bair, Scott J. Rodig, Philippe Armand, Reid W. Merryman, Alexey V. Danilov, Jennifer L. Crombie
Institutions: Brigham and Women's Hospital, Harvard University, Assistance Publique – Hôpitaux de Paris, Dana-Farber Cancer Institute, Hôpital Saint-Louis, The University of Texas MD Anderson Cancer Center, City Of Hope National Medical Center, City of Hope, University of Utah, Huntsman Cancer Institute, Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Memorial Sloan Kettering Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Wexner Medical Center, Vanderbilt University Medical Center, University of Colorado Cancer Center, Dana-Farber Brigham Cancer Center
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,157
OpenAlex ID: W7236568475
